As early as 1986, Ohno et al. [19] found that Grifola frondosa L E extracted from liquid-cultured Grifola frondosa mycelium had anti-tumor effect, and it was administered intraperitoneally to mice within 9 days after S 180 solid tumor was implanted, with the dose of100. Kodama et al. [20] investigated the curative effect of taking Grifola frondosa polysaccharide in tumor patients aged 22-57, and found that 58.3% of liver cancer patients, 68.8% of breast cancer patients and 62.5% of lung cancer patients were significantly relieved after using Grifola frondosa polysaccharide, while only 65,438+00% ~ 20% of patients with gastric cancer, leukemia and brain tumor were relieved. With the deepening of research, it was found that Grifola frondosa polysaccharide did not directly kill tumor cells, but activated the immune system of the body, thus inhibiting tumor growth, preventing tumor metastasis and preventing normal cells from becoming cancerous. After treating mice with macrophage inhibitor, the anti-tumor activity of Grifola frondosa polysaccharide decreased. When combined with radiotherapy and chemotherapy, it can enhance the therapeutic effect and reduce the side effects of radiotherapy and chemotherapy [2 1]. Takeyama et al. [22] think that Grifola frondosa polysaccharide can promote the cytotoxicity of T2 cells and show anti-tumor activity through host-mediated mechanism. Macrophages and T2 cells may play an important role. Adachi et al. showed that the anti-tumor mechanism of Grifola frondosa polysaccharide may be related to promoting the secretion of cytokines (such as IL-6, IL- 1 and TNF-α, etc.) by macrophages. ), and the production of these cytokines is intrinsically related to the formation of endotoxin, so Grifola frondosa polysaccharide is considered as a new type of macrophage activator [23].